Home Forums *News Top Industry News: December 19, 2022 – January 6, 2023

Top Industry News: December 19, 2022 – January 6, 2023

Home Forums *News Top Industry News: December 19, 2022 – January 6, 2023

    • Lauren Feldman

      Axios (January 4, 2023) Quris eyeing up to $100M in new funds

      Quris, an AI-powered prediction platform for clinical trials, is prepping to raise as much as $100 million in Series A capital, CEO Isaac Bentwich tells Axios exclusively.


      Endpoint News (January 3, 2023) Passage of FDA Modernization Act 2.0 clears the way to reduce animal testing

      While the future of drug development likely won’t be completely animal-free, thanks to the passage of the FDA Modernization Act 2.0, there may be less use of animals in situations where they aren’t necessary. The bill, which was added to the 2023 spending package that President Joe Biden signed into law last week, doesn’t ban animal testing outright, but it allows drug developers to use alternative methods to investigate the safety and effectiveness of a new drug.


      Genetic Engineering & Biotechnology News (December 30, 2022) Human Brain Organoids Implanted into Mice Connect to Animals’ Cortex and Respond to External Sensory Stimuli

      A research team says it has shown for the first time that human brain organoids implanted in mice have established functional connectivity to the animals’ cortex and responded to external sensory stimuli. The implanted organoids reacted to visual stimuli in the same way as surrounding tissues, an observation that researchers were able to make in real time over several months thanks to an experimental setup that combines transparent graphene microelectrode arrays and two-photon imaging.


      Forbes (December 29, 2022) AI’s Role In Accelerating Drug Discovery And Repurposing

      We’re all familiar with the dilemma: It takes an average of 9.5 to 15 years to develop a new drug at a cost as high as $2.6 billion, with only a fraction of the drugs making it to market. With AI and machine learning, the time and costs of drug discovery can be reduced dramatically. More importantly, patients can get faster access to novel treatments.


      MedCity News (December 26, 2022) By Eliminating Requirement for Animal Testing, FDA Modernization Act Allows Faster, More Cost-effective Drug Development

      Congress passed the FDA Modernization Act 2.0 last week removing the requirement to use animal testing in drug development. This will allow drug companies the option to use alternative safety-testing models when making new drug submissions. This is important because the Federal Food, Drug and Cosmetics Act of 1938, which is still in force, mandates animal testing for every new drug development protocol. Advocates of non-animal experimentation have argued that the cost of animal research is high—in dollars, in time, and in delays in approvals of beneficial drugs for human use.


      Forbes (December 21, 2022) Personalized Neuroscience: Are Human-Derived Brain Organoids The Answer?

      Imagine a futuristic society capable of curing devastating neurological disorders by recreating the brains’ of patients in a dish. Doing so allows them to tailor drug cocktails and therapeutic strategies to the specifics of each individual. Personalized neuroscience providing customized treatments. Except it is not a futuristic society. It sounds like it should be, but in fact it is real science taking place right now across a number of labs throughout the world.


      Science (December 20, 2022) Research gets a boost in final 2023 spending agreement

      Congress unveiled a belated $1.7 trillion spending bill on 20 December that keeps the U.S. government running for the next 9 months. Lawmakers did the best they could for basic research. But their desire to increase the defense budget kept them from delivering a major promised boost for the National Science Foundation (NSF) and held several other civilian agencies to small increases.


      Scrip Pharma Intelligence (December 20, 2022) Accelerated Approval Reforms Give US FDA More Power And Flexibility – With Some Gaps

      Pending legislation will give agency ability to require that confirmatory studies be underway at time of approval and expedited withdrawal process could allow FDA to skip a second advisory committee meeting, but Congress holds back on some agency requests for expanded authority.

Viewing 0 reply threads
  • You must be logged in to reply to this topic.